A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Juvenile myelomonocytic leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.